A Study of MEDI9253 in Combination With Durvalumab in Select Solid Tumors

Stopped early · Phase 1

Conditions studied: Solid Tumors

In brief

Study D7880C00001 is a first-in-human (FIH), Phase 1, open-label, multicenter, dose escalation and dose expansion study to evaluate the safety, tolerability, PK, pharmacodynamics, and preliminary efficacy of MEDI9253 in combination with durvalumab in adult participants with select advanced/metastatic solid tumors.

Key facts

Study ID

NCT04613492

Run by

AstraZeneca

People needed

40

Starts

2020-12-02

Expected to finish

2024-05-31

Last updated by the study team

2025-06-24

Who can join

Age: 18 and older, up to 101. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Participant must be at least 18 years old at signing of informed consent.
• Body weight > 35 kg at screening.

You may not qualify if…

• 1 Primary central nervous system (CNS) disease is excluded, as well as untreated or uncontrolled metastatic CNS involvement, leptomeningeal disease, or cord compression.
• NOTE: CNS disease that has been treated and stable/controlled for at least 3 months is permitted. Participants with CNS disease controlled via systemic steroids are not permitted.

Where it is running

• Research Site — St Louis, Missouri, United States
• Research Site — Buffalo, New York, United States
• Research Site — New York, New York, United States
• Research Site — New York, New York, United States
• Research Site — Pittsburgh, Pennsylvania, United States
• Research Site — Bordeaux, France
• Research Site — Toulouse, France
• Research Site — Villejuif, France

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.